| Autor: |
Pomeroy, Emily J, Anzalone, Andrew V, Podracky, Christopher J, Bloch, Noah B, Chang, Reyna, Dwivedi, Arika A, Laoharawee, Kanut, Wilhelm, Alan J, Waterman, David P, Tedeschi, Justin G, Arvindam, Upasana Sunil, Macari, Elizabeth R, Gori, Jennifer L, Duffield, Jeremy S |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4803-4803, 1p |
| Abstrakt: |
While CAR-T cell therapy represents a major advance in personalized immunotherapy, the autologous nature of commercially available CAR-T products have delayed its broad application beyond a subset of hematological malignancies. In particular, manufacturing autologous CAR-T therapies is costly and time-consuming, and success relies on the fitness of a patient's cells. An allogeneic off-the-shelf CAR-T product could overcome these cell quality and quantity issues and could be accessed on-demand. However, a successful allogeneic CAR-T product will require multiplex gene knockout in addition to stable CAR integration to prevent graft-versus-host disease (GvHD) and graft rejection by the patient's immune system. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
